Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00677053 · ClinicalTrials.gov registry record · Phase 2

Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes

A Phase 2 study of Acute Coronary Syndrome, sponsored by Takeda.

Completed
Registry status
Phase 2
Development phase
2,753
Enrollment target
20
Study locations

NCT00677053: Completed Phase 2 study of Acute Coronary Syndrome, sponsored by Takeda.

NCT00677053 is a Phase 2 study of Acute Coronary Syndrome that has completed, run by Takeda. The registered enrollment target is 2,753 participants, roughly in line with the 2,653-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target. The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00677053, a Phase 2 study of Acute Coronary Syndrome, has completed, sponsored by Takeda.

COMPLETED
Registry status
Phase 2
Development phase
2,753 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine the safety and tolerability of multiple doses of TAK-442once daily, (QD) or twice daily (BID), in subjects with acute coronary syndrome (unstable angina, myocardial infarction).

Conditions Studied

Acute Coronary Syndrome

Interventions

  • DRUG TAK-442

Study Locations (20)

Other

  • - Buenos Aires
  • - Bonheiden
  • - Genk
  • - Liège
  • - Porto Algere

Texas

  • - Houston
  • - Victoria

Alabama

  • - Birmingham

Arizona

  • - Tucson

Delaware

  • - Newark

District of Columbia

  • - Washington D.C.

Florida

  • - Pensecola

Iowa

  • - West Des Moines

Trial Details

FieldValue
Enrollment Target 2,753 participants
Start Date 2008-03
Est. Completion 2010-06
Phase Phase 2
Takeda

408 total trials

What the finished NCT00677053 record still lists

NCT00677053 is an interventional study that assigns participants to a tested intervention. Its 2,753 participants enrollment target places it among the larger protocols in the corpus, roughly in line with the 2,653-participant average among 40 other Acute Coronary Syndrome trials with a reported enrollment target.

The record links to 1 condition, with Acute Coronary Syndrome appearing as the primary indexed condition, and to 1 intervention - of which TAK-442 is the first listed.

NCT00677053 names 20 study sites across 15 states, led by Other, Texas, Alabama.

Frequently Asked Questions

What is clinical trial NCT00677053 about?

NCT00677053 is a clinical study titled "Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes". The purpose of this study is to determine the safety and tolerability of multiple doses of TAK-442once daily, (QD) or twice daily (BID), in subjects with acute coronary syndrome (unstable angina, myocardial infarction).

What is the current status of trial NCT00677053?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 2,753 participants. The study started on 2008-03. Estimated completion is 2010-06.

What conditions does trial NCT00677053 study?

This clinical trial studies the following conditions: Acute Coronary Syndrome.

What interventions are being tested in trial NCT00677053?

The interventions under investigation include: TAK-442 (DRUG).

Who is sponsoring clinical trial NCT00677053?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00677053 being conducted?

This trial has 20 study locations across Alabama, Arizona, Delaware, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Coronary Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00677053's enrollment target sits among peer trials

2,753 9th of 40 higher than 32 of 40 other Acute Coronary Syndrome trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Acute Coronary Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05443737 · 2,800 participants · Phase 3

    Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients

  • NCT05899439 · 2,800 participants

    Immune Function and the Progression to T1D

  • NCT06089109 · 2,800 participants · NA

    Creating VIP Corps to Reduce Maternal Deaths

  • NCT06345339 · 2,800 participants · Phase 2

    A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00677053, the US trial registry maintained by the National Library of Medicine. NCT00677053 (large enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.